补益肺肾法治疗慢性阻塞性肺疾病稳定期肺肾气虚型的临床观察
发布时间：2018-11-16 12:25
【摘要】：目的:通过观察补益肺肾法对慢性阻塞性肺疾病稳定期肺肾气虚型患者的临床疗效,验证补益肺肾法的可行性,对中医药治疗慢性阻塞性肺疾病稳定期提供一种新的有效的方法。材料与方法:本次临床研究对象均为2014年12月-2016年6月期间于辽宁中医药大学附属第二医院肺病门诊就诊的慢性阻塞性肺疾病稳定期肺肾气虚型患者,采用随机分组的方法,将65例符合纳入标准的患者分为治疗组和对照组,治疗组32例,对照组33例。对照组采用西医常规治疗:沙美特罗替卡松粉吸入剂(商品名:舒利迭),规格:50ug/500ug,每次1吸,每日2次;治疗组在西医常规治疗的基础上加用以补益肺肾为法的保金益肾膏。疗程均为三个月。于治疗前后测评两组单项症状评分,中医证候总评分,肺功能,生活质量评估问卷评分(CAT)等相关指标。于治疗前和随访后测评两组急性加重次数指标。并用SPSS17.0统计软件包对其结果进行统计分析。结果:1.治疗组与对照组在性别、年龄、病程、肺功能分级、症状评分、生活质量问卷评分、急性加重次数上均无显著性差异(P0.05),具有可比性。2.急性加重次数方面:治疗组随访后急性加重次数减少(P0.05);对照组随访后急性加重次数没有减少(P0.05);随访后两组比较有显著性差异(P0.05)。3.临床症状方面:治疗组治疗后喘息,气短,咳嗽,咯痰,恶风,腰膝酸软等六项症状评分均有所下降(P0.05);对照组治疗后喘息,气短,咳嗽,咯痰,恶风等五项症状评分均有所下降(P0.05);两组治疗后在咳嗽,气短,恶风,腰膝酸软等四项指标方面有显著性差异(P0.05),治疗组优于对照组。4.中医证候积分方面:治疗组治疗后中医证候总积分有所下降(P0.05);对照组治疗后中医证候总积分有所下降(P0.05);治疗后组间比较有显著性差异(P0.05),治疗组优于对照组。5.肺功能方面:治疗组治疗后FEV1%、FEV1/FVC%指标有所改善(P0.05);对照组治疗后FEV1%、FEV1/FVC%指标有所改善(P0.05);治疗后组间比较无显著性差异(P0.05)。6.生存质量方面:治疗组治疗后生活质量评分有所改善(P0.05);对照组治疗后生活质量评分有所改善(P0.05);治疗后组间比较有显著性差异(P0.05),治疗组优于对照组。结论:通过对补益肺肾法治疗慢性阻塞性肺疾病稳定期肺肾气虚型患者的临床观察,疗效显著,说明补益肺肾法针对慢性阻塞性肺疾病稳定期的治疗有效。
[Abstract]:Objective: to observe the clinical effect of tonifying the lung and kidney in patients with chronic obstructive pulmonary disease (COPD) during the stable period of lung and kidney qi deficiency, and to verify the feasibility of tonifying the lung and kidney. It provides a new and effective method for the treatment of chronic obstructive pulmonary disease. Materials and methods: the subjects of this clinical study were all patients with chronic obstructive pulmonary disease (COPD) in stable phase of lung and kidney qi deficiency in the second affiliated Hospital of Liaoning University of traditional Chinese Medicine from December 2014 to June 2016. 65 patients were divided into treatment group (n = 32) and control group (n = 33). The control group was treated with routine western medicine: salmeterol fluticasone powder inhaler (commodity name: Schullide), specification: 50ugr / 500ug. once a day, twice a day; Treatment group on the basis of western medicine routine treatment plus to tonify the lung and kidney as the method of Baojin Yishen ointment. The course of treatment was three months. The single symptom score, TCM syndrome score, lung function, quality of life assessment scale (CAT) were evaluated before and after treatment. The indexes of acute exacerbation were measured before treatment and after follow-up. The results were analyzed by SPSS17.0 software package. The result is 1: 1. There was no significant difference between treatment group and control group in sex, age, course of disease, pulmonary function grade, symptom score, quality of life questionnaire score, acute exacerbation times (P0.05). Acute exacerbation times: the treatment group after follow-up acute exacerbation times decreased (P0.05); the control group after follow-up acute exacerbation times did not decrease (P0.05); after follow-up there was a significant difference between the two groups (P0.05). Clinical symptoms: the treatment group after the treatment of wheezing, shortness of breath, cough, sputum, evil wind, waist and knee weakness and other six symptom scores have decreased (P0.05); In the control group, the scores of wheezing, shortness of breath, cough, sputum and evil wind were all decreased after treatment (P0.05). There were significant differences between the two groups in cough, shortness of breath, bad wind, waist and knee weakness and other four indexes (P0.05), the treatment group was better than the control group. 4. TCM syndromes integral: treatment group after treatment the total score of TCM syndromes decreased (P0.05); the control group after treatment of TCM syndromes total score decreased (P0.05); After treatment there was a significant difference between the groups (P0.05), the treatment group was better than the control group. Lung function: treatment group after treatment FEV1%,FEV1/FVC% index improved (P0.05); control group after treatment FEV1%,FEV1/FVC% index improved (P0.05); after treatment there was no significant difference between groups (P0.05). Quality of life: the quality of life score improved after treatment in the treatment group (P0.05), the quality of life score improved after treatment in the control group (P0.05). After treatment there was significant difference between the groups (P0.05), the treatment group was better than the control group. Conclusion: the clinical observation of tonifying the lung and kidney method in treating chronic obstructive pulmonary disease patients with deficiency of lung and kidney qi in stable period shows that the method of tonifying the lung and kidney is effective in treating chronic obstructive pulmonary disease in stable period.
【学位授予单位】：辽宁中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259
本文编号：2335512
[Abstract]:Objective: to observe the clinical effect of tonifying the lung and kidney in patients with chronic obstructive pulmonary disease (COPD) during the stable period of lung and kidney qi deficiency, and to verify the feasibility of tonifying the lung and kidney. It provides a new and effective method for the treatment of chronic obstructive pulmonary disease. Materials and methods: the subjects of this clinical study were all patients with chronic obstructive pulmonary disease (COPD) in stable phase of lung and kidney qi deficiency in the second affiliated Hospital of Liaoning University of traditional Chinese Medicine from December 2014 to June 2016. 65 patients were divided into treatment group (n = 32) and control group (n = 33). The control group was treated with routine western medicine: salmeterol fluticasone powder inhaler (commodity name: Schullide), specification: 50ugr / 500ug. once a day, twice a day; Treatment group on the basis of western medicine routine treatment plus to tonify the lung and kidney as the method of Baojin Yishen ointment. The course of treatment was three months. The single symptom score, TCM syndrome score, lung function, quality of life assessment scale (CAT) were evaluated before and after treatment. The indexes of acute exacerbation were measured before treatment and after follow-up. The results were analyzed by SPSS17.0 software package. The result is 1: 1. There was no significant difference between treatment group and control group in sex, age, course of disease, pulmonary function grade, symptom score, quality of life questionnaire score, acute exacerbation times (P0.05). Acute exacerbation times: the treatment group after follow-up acute exacerbation times decreased (P0.05); the control group after follow-up acute exacerbation times did not decrease (P0.05); after follow-up there was a significant difference between the two groups (P0.05). Clinical symptoms: the treatment group after the treatment of wheezing, shortness of breath, cough, sputum, evil wind, waist and knee weakness and other six symptom scores have decreased (P0.05); In the control group, the scores of wheezing, shortness of breath, cough, sputum and evil wind were all decreased after treatment (P0.05). There were significant differences between the two groups in cough, shortness of breath, bad wind, waist and knee weakness and other four indexes (P0.05), the treatment group was better than the control group. 4. TCM syndromes integral: treatment group after treatment the total score of TCM syndromes decreased (P0.05); the control group after treatment of TCM syndromes total score decreased (P0.05); After treatment there was a significant difference between the groups (P0.05), the treatment group was better than the control group. Lung function: treatment group after treatment FEV1%,FEV1/FVC% index improved (P0.05); control group after treatment FEV1%,FEV1/FVC% index improved (P0.05); after treatment there was no significant difference between groups (P0.05). Quality of life: the quality of life score improved after treatment in the treatment group (P0.05), the quality of life score improved after treatment in the control group (P0.05). After treatment there was significant difference between the groups (P0.05), the treatment group was better than the control group. Conclusion: the clinical observation of tonifying the lung and kidney method in treating chronic obstructive pulmonary disease patients with deficiency of lung and kidney qi in stable period shows that the method of tonifying the lung and kidney is effective in treating chronic obstructive pulmonary disease in stable period.
【学位授予单位】：辽宁中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259
【参考文献】
相关期刊论文 前10条
1 姚青平;董克州;;针药并治法对肺肾两虚型慢性阻塞性肺疾病缓解期血清氧化指标及肺功能的影响[J];山西中医;2017年01期
2 刘向龙;刘猛;于明克;左玉芝;杨玲;;补益肺肾汤加减联合异丙托溴铵治疗慢性阻塞性肺疾病稳定期效果观察[J];临床误诊误治;2016年08期
3 陈天良;;补肺益肾汤治疗肺肾气虚型慢性阻塞性肺疾病稳定期的临床效果[J];临床合理用药杂志;2015年24期
4 刘明慧;王美;周洵;;补虚泻实法针药并治慢性阻塞性肺疾病经验[J];世界最新医学信息文摘;2015年65期
5 傅开龙;林侃;;穴位贴敷治疗慢性阻塞性肺疾病患者80例临床观察[J];中医杂志;2015年11期
6 张玉龙;王梦月;杨静玉;李晓波;;炙甘草化学成分及药理作用研究进展[J];上海中医药大学学报;2015年03期
7 宫静;陈宁;郝小梅;李慧;;培土生金方对慢性阻塞性肺疾病稳定期患者营养状态和免疫功能的影响[J];中国中西医结合杂志;2015年05期
8 韩雪娇;郭娜;朱美宣;于涛;;红景天苷药理作用及其作用机理研究进展[J];中国生化药物杂志;2015年01期
9 袁航;曹树萍;陈抒云;过立农;郑健;林瑞超;;淫羊藿的化学成分及质量控制研究进展[J];中草药;2014年24期
10 翟洪波;;活血化瘀方配合西药治疗慢性阻塞性肺疾病疗效观察[J];陕西中医;2014年11期
相关博士学位论文 前1条
1 梁晋如;山茱萸的化学成分及其生物活性研究[D];西北大学;2014年
相关硕士学位论文 前2条
1 孙宇峰;近20年中医药治疗慢性阻塞性肺疾病稳定期的文献研究[D];山东中医药大学;2014年
2 齐莹;慢性阻塞性肺疾病稳定期综合评估与中医证素的相关性研究[D];北京中医药大学;2014年
，本文编号：2335512
本文链接：https://www.wllwen.com/zhongyixuelunwen/2335512.html
最近更新
教材专著
